Sign in

OPRX on Nasdaq

OptimizeRx Corp

In its 2026 annual report the company says: “OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers. We leverage our proprietary technology solutions and partnerships to help our clients develop and execute highly individualized and targeted marketing campaigns to drive physician and patient engagement and to enhance patient care.”4 It is headquartered in Waltham, Massachusetts.1 Its shares trade on Nasdaq under the symbol OPRX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with CASS INFORMATION SYSTEMS INC, Bridger Aerospace Group Holdings, Inc. or FiscalNote Holdings, Inc., or pick any stock.

  • TickerOPRX on Nasdaq1
  • IndustryServices-Business Services, NEC1
  • HeadquartersWaltham, Massachusetts1
  • Incorporated inNV2
  • Business address260 Charles Street, Suite 302, Waltham, Ma 024532
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

OptimizeRx is a leading digital healthcare technology company that is redefining how life sciences brands engage with, market their services and products to, and support patients and healthcare providers. We leverage our proprietary technology solutions and partnerships to help our clients develop and execute highly individualized and targeted marketing campaigns to drive physician and patient engagement and to enhance patient care. OptimizeRx is a Nevada corporation and was founded in 2006 in Rochester, Michigan, as a healthcare technology company delivering various types of messages to target audiences, including coupons and co-pays directly to physicians and pharmacists through electronic health record (“EHR”) systems and ePrescribing (“eRx”) platforms. Over time, the demand for different types of communication and marketing solutions among life sciences organizations, healthcare prof…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

67.3%Gross margin5
10.7%Operating margin5
4.7%Net margin5
18.8%Revenue growth, 20255
4.0%Return on equity5
0.17×Debt to equity5
$18.7MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Life Science Companies brought in 100% of the revenue OptimizeRx Corp broke down this way in fiscal 2025.

  1. Life Science Companies$109.2M5100%up 28% from 2024
  2. Other Revenue$215.0K50%down 97% from 2024
Products and services by year
Products and services20242025
Life Science Companies$85.5M$109.2M
Other Revenue$6.7M$215.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue33¢$35.8M
  • Other costs61¢$66.6M
  • Income tax2¢$1.8M
  • Profit5¢$5.1M

Out of $109.4M in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending0¢$58.0K
  • Kept or used elsewhere100¢$18.7M

Out of $18.7M of cash from operations.5

Financial statements

Revenue67895$109.4M in 2025+345% since 2019
0$50.0M$100.0M$150.0M2019: $24.6M$24.6M20192020: $43.3M$43.3M2020+76%2021: $4.5M$4.5M2021−90%2022: $1.0M$1.0M2022−77%2023: $71.5M$71.5M2023+6878%2024: $92.1M$92.1M2024+29%2025: $109.4M$109.4M2025+19%
Gross profit6781095$73.6M in 2025+377% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $15.4M$15.4M20192020: $24.1M$24.1M2020+56%2021: $35.6M$35.6M2021+48%2022: $39.0M$39.0M2022+9%2023: $42.9M$42.9M2023+10%2024: $59.4M$59.4M2024+38%2025: $73.6M$73.6M2025+24%
Operating income6781095$11.7M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M$20.0M2019: -$3.7M-$3.7M20192020: -$2.1M-$2.1M2020−42%2021: $361.1K$361.1K20212022: -$12.3M-$12.3M20222023: -$26.4M-$26.4M2023+115%2024: -$13.7M-$13.7M2024−48%2025: $11.7M$11.7M2025
Net income6781095$5.1M in 2025
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$3.1M-$3.1M20192020: -$2.2M-$2.2M2020−30%2021: $378.1K$378.1K20212022: -$11.4M-$11.4M20222023: -$17.6M-$17.6M2023+54%2024: -$20.1M-$20.1M2024+14%2025: $5.1M$5.1M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Net revenue$109.4M$92.1M
Cost of revenues, exclusive of depreciation and amortization presented separately below$35.8M$32.7M
Gross profit$73.6M$59.4M
Stock-based compensation$7.0M$11.5M
Impairment charges$368.0K$7.5M
Depreciation and amortization$4.3M$4.3M
Other general and administrative expenses$50.2M$49.8M
Total operating expenses$61.9M$73.1M
Income (loss) from operations$11.7M-$13.7M
Interest expense-$5.3M-$6.2M
Other income$198.0K$152.0K
Interest income$353.0K$329.0K
Total other expenses, net-$4.7M-$5.7M
Income (loss) before provision for income taxes$7.0M-$19.4M
Income tax expense-$1.8M-$725.0K
Net income (loss)$5.1M-$20.1M
Weighted average number of shares outstanding basic (in shares)18.6M shares18.3M shares
Weighted average number of shares outstanding diluted (in shares)19.0M shares18.3M shares
Income (loss) per share basic (in dollars per share)$0.28-$1.10
Income (loss) per share diluted (in dollars per share)$0.27-$1.10

Compare OptimizeRx Corp with another company

Corporate structure

OptimizeRx Corp sits at the top of its group. 3 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of OptimizeRx Corp

  • OptimizeRx Corp Waltham, Massachusetts
    • Cyberdiet, a controlled foreign corporation located in Subsidiary · Israel
    • OptimizeRx, d.o.o. (formerly known as CareSpeak Communications, d.o.o.), a controlled foreign corporation located in Subsidiary · Croatia

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What OptimizeRx Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Computer equipment and software$397.0K9 Dec 31, 2024$407.0K9 Dec 31, 2023−2.5%
Property and equipment, before depreciation$457.0K5 Dec 31, 2025$408.0K5 Dec 31, 2024+12.0%
Accumulated depreciation$351.0K5 Dec 31, 2025$258.0K5 Dec 31, 2024+36.0%
Property and equipment, net$106.0K5 Dec 31, 2025$150.0K5 Dec 31, 2024−29.3%
Operating-lease assets (leased space)$404.0K5 Dec 31, 2025$366.0K5 Dec 31, 2024+10.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$23.4M5 Dec 31, 2025$13.4M5 Dec 31, 2024+74.6%
Marketable securities, current$05 Dec 31, 2025$05 Dec 31, 2024

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$70.9M5 Dec 31, 2025$70.9M5 Dec 31, 20240%
Finite-lived intangibles, gross$52.4M5 Dec 31, 2025$53.0M5 Dec 31, 2024−1.1%
Accumulated amortization$11.6M5 Dec 31, 2025$7.5M5 Dec 31, 2024+55.1%
Finite-lived intangibles, net$40.8M5 Dec 31, 2025$45.5M5 Dec 31, 2024−10.4%

Properties, in its own words

Currently, we do not own any real estate. As of December 31, 2025, we had operating leases for office space in four multi-tenant facilities. The leases include office spaces in Waltham, Massachusetts, Clarkston, Michigan, Scottsdale, Arizona, and Zagreb, Croatia. Our principal executive offices are located at 260 Charles Street, Waltham, Massachusetts 02453.

The lease in Waltham, Massachusetts expires July 31, 2026, and has a monthly rent with escalating payments of $5.8 to $6.8. The lease in Clarkston, Michigan expires November 30, 2027, and has a monthly rent of $2.5. The lease in Scottsdale, Arizona expires July 31, 2028, and has a monthly rent with escalating payments of $7.9 to $8.5. The lease in Zagreb, Croatia expires on June 30, 2028, but grants the tenant the option to terminate the lease with 30-day notice before each lease anniversary, and has a monthly rent of approximately $3.3.

Item 2 of the 10-K filed Mar 12, 2026.4

Leadership

Who has led OptimizeRx Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. David Lester2009–2011
  2. David Harrell2011–2015
  3. William J. Febbo2016–2025
  4. Stephen L. Silvestro2025–now

Chair

  1. David Harrell2009–2010
  2. David Lester2010

President

  1. David Harrell2011
  2. David Lester2011
  3. Miriam J. Paramore2017–2021

Chief financial officer

  1. Douglas P. Baker2014–2021
  2. Edward Stelmakh2021–now

Chief operating officer

  1. David Lester2014
  2. Edward Stelmakh2021–2025
  3. Brendan W. Merrell2025–now
2010201520202025
Board members and other officers (27)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Cyberdiet, a controlled foreign corporation located in Israel3
  • OptimizeRx, d.o.o. (formerly known as CareSpeak Communications, d.o.o.), a controlled foreign corporation located in Croatia3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 12, 20268-K Results of operations; Executive or director change; Regulation FD disclosure48
  2. Jun 12, 20268-K Executive or director change; Shareholder vote49
  3. Jun 5, 20268-K Executive or director change50
  4. May 12, 20268-K Entered a material agreement; Ended a material agreement; Results of operations51
  5. Apr 9, 20268-K Executive or director change; Regulation FD disclosure52
  6. Mar 30, 20268-K Change of auditor53
  7. Mar 5, 20268-K Entered a material agreement; Results of operations; Other events54
  8. Nov 6, 20258-K Results of operations55
  9. Aug 25, 2025New chief executive Stephen L. Silvestro becomes CEO13
  10. Aug 19, 20258-K Executive or director change; Regulation FD disclosure56
  11. Aug 7, 20258-K Results of operations57
  12. Jun 24, 20258-K Executive or director change; Regulation FD disclosure58
  13. Jun 16, 20258-K Shareholder vote59
  14. Feb 25, 2016New chief executive William J. Febbo becomes CEO14
  15. Jun 1, 2011New chief executive David Harrell becomes CEO15
  16. Jun 22, 2009New chief executive David Lester becomes CEO16

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $0.10 a share, on Nov 6, 2025.60

When it reported results

  1. Aug 12, 2026Reported quarterly or annual results48
  2. May 12, 2026Reported quarterly or annual results51
  3. Mar 5, 2026Reported quarterly or annual results54
  4. Nov 6, 2025Reported quarterly or annual results55
  5. Aug 7, 2025Reported quarterly or annual results57
  6. May 12, 2025Reported quarterly or annual results61
  7. Mar 12, 2025Reported quarterly or annual results62
  8. Nov 13, 2024Reported quarterly or annual results63

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

338 filings to the SEC since October 2021: 6 annual reports, 18 quarterly reports, 50 major events, 209 insider forms, 33 large holders, 22 other. The latest 20:

  1. Oct 2, 20264 EDGAR
  2. Sep 2, 20264 EDGAR
  3. Aug 24, 20264 EDGAR
  4. Aug 24, 20264 EDGAR
  5. Aug 24, 20264 EDGAR
  6. Aug 24, 20264 EDGAR
  7. Aug 24, 20264 EDGAR
  8. Aug 24, 20264 EDGAR
  9. Aug 24, 20264 EDGAR
  10. Aug 24, 20264 EDGAR
  11. Aug 24, 20264 EDGAR
  12. Aug 20, 2026S-8 REGISTRATION STATEMENT EDGAR
  13. Aug 14, 2026SCHEDULE 13G EDGAR
  14. Aug 13, 202610-Q EDGAR
  15. Aug 12, 20268-K EDGAR
  16. Jul 29, 2026SCHEDULE 13G/A EDGAR
  17. Jul 22, 2026SCHEDULE 13G EDGAR
  18. Jun 12, 20268-K CURRENT REPORT EDGAR
  19. Jun 10, 20264 EDGAR
  20. Jun 10, 20264 EDGAR

The 338 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 9 buys and 17 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 19, 2025Stelmakh EdwardChief Finance & Strat OfficerSale1,388$13.51$18.8KForm 4
Oct 3, 2025Silvestro Stephen LChief Executive OfficerSale1,620$18.75$30.4KForm 4
Aug 28, 2025Spangler Patrick DDirectorSale11,120$17.49$194.5KForm 4
Mar 14, 2025Lang James PaulDirectorBuy321,408$7.60$2.4MForm 4
Dec 12, 2024FEBBO WILLIAM JCEOBuy20,000$5.01$100.2KForm 4
Jan 9, 2024Odence-Ford MarionChief Legal & Admin OfficerSale4,000$15.19$60.8KForm 4
Aug 26, 2022Odence-Ford MarionChief Legal & Admin OfficerBuy1,000$15.75$15.8KForm 4
Aug 22, 2022FEBBO WILLIAM JCEOBuy10,700$15.29$163.6KForm 4
Aug 19, 2022Lang James PaulDirectorBuy6,000$16.45$98.7KForm 4
Aug 19, 2022FEBBO WILLIAM JCEOBuy5,400$16.18$87.4KForm 4
Aug 16, 2022Silvestro Stephen LChief Executive OfficerBuy3,200$15.66$50.1KForm 4
Aug 16, 2022Vos Ellen O'ConnorDirectorBuy500$15.91$8.0KForm 4
Aug 15, 2022Stelmakh EdwardChief Finance & Strat OfficerBuy3,000$15.43$46.3KForm 4
Feb 18, 2022FEBBO WILLIAM JCEOSale16,666$43.73$728.8KForm 4
Jan 18, 2022FEBBO WILLIAM JCEOSale16,666$47.27$787.8KForm 4
Dec 17, 2021Silvestro Stephen LChief Executive OfficerSale13,241$54.87$726.5KForm 4
Dec 15, 2021FEBBO WILLIAM JCEOSale16,666$54.55$909.1KForm 4
Dec 2, 2021Paramore Miriam JPRESIDENT AND CSOSale3,558$61.48$218.7KForm 4
Nov 17, 2021Silvestro Stephen LChief Executive OfficerSale13,241$73.98$979.6KForm 4
Nov 15, 2021FEBBO WILLIAM JCEOSale16,666$82.18$1.4MForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Stephen SilvestroChief Executive Officer48$500.0K$2.7M75
2025Theresa GrecoChief Commercial Officer$367.5K$1.5M75
2025Edward StelmakhChief Financial & Strategy Officer$450.0K$1.5M75
2024Edward StelmakhChief Financial & Strategy Officer$425.0K$1.0M75
2024Stephen SilvestroChief Executive Officer48$400.0K$973.1K75

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Whetstone Capital Advisors, LLC1,508,303$8.6M2.3%No change
Royce & Associates LP1,089,398$6.2M0.1%+201,368
Vanguard Capital Management LLC699,604$4.0M0.0%+14,155
Kennedy Capital Management LLC644,150$3.7M0.1%−12,108
Rice Hall James & Associates, LLC633,842$3.6M0.2%+31,921
Blair William & Co/il607,925$3.5M0.0%−7,067
Aqr Capital Management LLC583,956$3.3M0.0%+369,002
Dimensional Fund Advisors LP477,687$2.7M0.0%−85,883
BlackRock, Inc.445,382$2.5M0.0%−718,119
Parkman Healthcare Partners LLC350,347$2.0M0.2%−379,022
AWM Investment Company, Inc.240,421$1.4M0.1%+10,000
Geode Capital Management, LLC207,345$1.2M0.0%−184,784
Vanguard Portfolio Management LLC169,538$969.8K0.0%−161,499
Renaissance Technologies LLC167,700$959.2K0.0%−49,156
Marshall Wace, Llp162,186$927.7K0.0%+130,900
P.a.w. Capital Corp160,000$915.2K0.7%+70,000
Citadel Advisors LLC157,992$903.7K0.0%New
Morgan Stanley156,314$894.1K0.0%+79,946
Mink Brook Asset Management LLC141,235$807.9K0.4%New
D. E. Shaw & Co., Inc.138,084$789.8K0.0%−4,839
Jane Street Group, LLC122,086$698.3K0.0%New
Goldman Sachs Group Inc105,037$600.8K0.0%−253,406
Quantinno Capital Management LP99,124$567.0K0.0%+50,102
Vanguard Fiduciary Trust Co97,999$560.6K0.0%−13,130
Trexquant Investment LP89,666$512.9K0.0%−47,208

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How OptimizeRx Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROptimizeRx Corp1
  • CIK0001448431
  • Employer ID (EIN)26-12653814
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inNevada4
  • Fiscal year endsDecember 311
  • Industry code (SIC)7389 Services-Business Services, NEC1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address260 Charles Street, Suite 302, Waltham, MA 024531
  • Phone248-651-65581
  • Shares outstanding18,835,951 as of Jul 30, 202612
  • Public float$240.9M as of Jun 30, 20254
  • AuditorUHY LLP, Sterling Heights, Michigan PCAOB ID 1195; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceNov 12, 20081
  • Filings1,047 in all: 4 (401), 8-K (322), 10-Q (53), 3 (32), SC 13G/A (25), SC 13G (24), 10-K (18), CORRESP (16)1
    All 42 form types

    SC 13D/A (13), 4/A (11), UPLOAD (11), 8-K/A (9), EFFECT (9), S-1/A (9), DEF 14A (8), S-8 (8), 424B3 (6), 424B5 (6), SC 13D (6), SCHEDULE 13G/A (6), 144 (5), NT 10-Q (5), S-1 (5), 10-Q/A (4), D (4), SCHEDULE 13G (4), 10-K/A (3), ARS (3), NT 10-K (3), DEFA14A (2), POS AM (2), S-3 (2), S-8 POS (2), SCHEDULE 13D/A (2), 8-A12B (1), 8-A12G (1), CERT (1), DEF 14C (1), DFAN14A (1), S-3/A (1), S-3ASR (1), SCHEDULE 13D (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Apr 30, 2026
    Latest 8-K (8-K) Aug 12, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001OPRXNASDAQ

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks OptimizeRx Corp names in Item 1A of its 10-K filed Mar 12, 2026: 40 risks under these headings, as written.4

  • Risks Related to Our Financial Position
  • We have a history of losses, and may not be able to achieve profitability, or, if achieved, sustain profitability.
  • We may need to raise additional capital to grow our business and may not be able to do so on favorable terms, if at all.
  • Servicing debt and funding other obligations requires a significant amount of cash, and our ability to generate sufficient cash depends on many factors, some of which are beyond our control.
  • Restrictions in our Term Loan could adversely affect our business, financial condition, results of operations, ability to make distributions, and the value of our securities.
  • Risks Related to Our Business: Our Industry, Operations, and Competition
  • Seasonal trends in the pharmaceutical brand marketing industry could affect our operating results.
  • Developing and implementing new and updated applications, features and services for our solutions may be more difficult than expected, may take longer and cost more than expected and may not result in sufficient increases in revenue to justify the costs.
  • Any failure to offer high-quality customer support for our solutions may adversely affect our relationships with our customers and harm our financial results.
  • We are dependent on a concentrated group of customers, and the loss of one or more of any of the pharmaceutical brands that purchase our solutions could cause our revenue to decline.
  • If we are unable to maintain our contracts with electronic prescribing platforms and electronic health record systems, our business will suffer.
  • Our agreements with eRx and EHR channel partners could be subject to audit.
The other 30 risks
  • If we fail to attract new customers or retain and expand existing customers, our business and future prospects may be materially and adversely impacted.
  • We expect to face increasing competition in the markets for our solutions.
  • Developments in the healthcare industry could adversely affect our business.
  • Risks Related to Regulatory Matters
  • Actual or perceived failures to comply with applicable laws and regulations that affect the healthcare industry, including data protection, privacy and security, fraud and abuse laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.
  • Our operations may be impacted by changes to current regulations and future legislation.
  • If our customers’ drug prices are reduced as a result of MFN pricing initiatives or other similar regulations, our business could be adversely affected.
  • If our customers, partners, and third-party providers fail to comply with the extensive and changing landscape of legal and regulatory requirements affecting the pharmaceutical and healthcare industries, they could face increased costs and/or penalties, which could lead to us losing business.
  • Risks Related to Our Intellectual Property and Technology
  • We are dependent, in part, on our intellectual property. If we are not able to protect our proprietary rights or if those rights are invalidated or circumvented, our business may be adversely affected.
  • Cybersecurity incidents could disrupt business operations, result in the loss of critical and confidential information, and adversely impact our reputation and results of operations.
  • We may be unable to support our technology to further scale our operations successfully.
  • Our business will suffer if our network systems fail or become unavailable.
  • The use of AI technology in our operations and IT infrastructure could improve internal processes, but could pose security risks and privacy risks; the use of AI technology also faces regulatory uncertainty and scrutiny given that AI technology is rapidly growing and evolving.
  • Related to Managing Our Growth
  • If we are unable to manage growth, our operations could be adversely affected.
  • We may not be able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully.
  • Our acquisition activities may disrupt our ongoing business and may involve increased expenses, and we may not realize the financial and strategic goals contemplated at the time of a transaction.
  • Risks Related to Inflation, Interest Rates, and Other Adverse Economic Conditions
  • Interest rate increases may adversely affect our financial condition and results of operations.
  • We could be subject to economic, political, regulatory and other risks arising from our international operations.
  • Inflation, the current interest rate environment, and other adverse economic conditions may adversely affect our business, results of operations and financial condition.
  • Impairment charges for goodwill or other long-lived assets may need to be recognized, lose a major customer or experience changes to the regulatory environment affecting pharmaceutical advertising restricting the use of our technology.
  • Market conditions could adversely change and our earnings could decline resulting in charges to impair intangible assets, such as goodwill.
  • Geopolitical events may affect our business and our customer base and have a material adverse impact on our sales and operating results.
  • General Risk Factors
  • Our business and growth may suffer if we are unable to attract and retain members of our senior management team and other key employees.
  • The impact and effects of public health crises, pandemics and epidemics could have a material adverse effect on our business, prospects, financial condition, and operating results.
  • Risks Relating to Our Common Stock
  • If a market for our common stock is not maintained, shareholders may be unable to sell their shares.
  • The market price of our common stock may be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control.
  • We do not expect to pay dividends in the foreseeable future and any return on investment may be limited to the value of our common stock.
  • Certain provision of our articles of incorporation, bylaws and Nevada law may discourage takeover attempts and business combinations that shareholders might consider in their best interests.
  • Actions of activist stockholders could be disruptive and costly and could adversely affect our results of operations, financial condition, and/or share price.
  • Risks Related to Being a Public Company
  • We have identified a material weakness in our internal control over financial reporting. Failure to remediate the material weakness or any other material weaknesses that we identify in the future could result in material misstatements in our future financial statements.
  • Conflicting views on environmental, social and governance matters may have a negative impact on our business, impose additional costs on us, and expose us to additional risks.

Legal proceedings

From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are currently not a party to any material legal or administrative proceedings, and we are not aware of any pending or threatened material legal or administrative proceedings against us.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75